Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155109 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL11971807 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL177081 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL1595257 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL11026742 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL1250842 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL14325015 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL2811047 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL14393350 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R | |
| SCHEMBL10209588 | 1.00 | MAPK14 (0.49) | MAPK14RETCAMK1DHDAC6TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422729-A | A kind of chirality azepine polycyclic alcaloid and its synthetic method | 中南民族大学 | 2019-03-05 | — | — | CN | claimed |
| US-7820715-B2 | Crystal comprising (2R)-2-propyloctanoic acid and amine | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | claimed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-20080090907-A1 | Crystal Comprising (2R)-2-Propyloctanoic Acid and Amine | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | claimed |
| EP-1741697-A1 | CRYSTAL COMPRISING (2R)-2-PROPYLOCTOIC ACID AND AMINE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | claimed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | claimed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | claimed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | claimed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | claimed |
| WO-2000006525-A9 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000006525-A2 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-10 | — | — | WO | claimed |
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4568945-A1 | HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4554569-A1 | AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS | Oxford Antibiotic Group GmbH (AT) | 2025-05-21 | — | — | EP | disclosed |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | disclosed |
| EP-0635485-A1 | TETRAHYDROPHTHALAMIDE DERIVATIVE, INTERMEDIATE FOR PRODUCING THE SAME, PRODUCTION OF BOTH, AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5210220-A | METHOD FOR PREPARING DERIVATIVES OF ASCORBIC ACID | HOFFMANN-LA ROCHE INC. (US) | 1993-05-11 | — | — | US | disclosed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | disclosed |
| EP-0471805-A1 | METHOD FOR PREPARING DERIVATIVES OF ASCORBIC ACID. | HOFFMANN LA ROCHE (CH) | 1992-02-26 | — | — | EP | disclosed |
| WO-1991013895-A1 | METHOD FOR PREPARING DERIVATIVES OF ASCORBIC ACID | F.HOFFMANN-LA ROCHE AG (CH) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090907-A1 | Crystal Comprising (2R)-2-Propyloctanoic Acid and Amine | TAS2R5, FFAR2, HRH2 | MAPK14 2620/4885RET 1132/4885CAMK1D 4203/4885 |
| US-12472271-B2 | HDAC6 inhibitors and imaging agents | HDAC1, HDAC6, HDAC11 | MAPK14 2524/4885RET 4629/4885CAMK1D 2508/4885 |
| US-20250120982-A1 | COVALENT TARGETING OF E3 LIGASES | STUB1, XIAP, RBX1 | MAPK14 4296/4885RET 3655/4885CAMK1D 1981/4885 |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | TKFC, NISCH, PTGIS | MAPK14 1762/4885RET 1794/4885CAMK1D 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.